Zochling, JM, Sieper, J, Braun, J
Objective. To create a core set of measurement concepts for use in the creation and maintenance of anti-tumor necrosis factor-α patient registries in ankylosing spondylitis (AS). Methods. A...
Zochling, JM, Sieper, J, Braun, J
Objective. To create a core set of measurement concepts for use in the creation and maintenance of anti-tumor necrosis factor-α patient registries in ankylosing spondylitis (AS). Methods. A...
Kobelt, G, Sobocki, P, Sieper, J, Braun, J
Abstract is not available.
Baraliakos, X, Brandt, J, Listing, J, Haibel, H, Rudwaleit, HM, Sieper, J, ...
No abstract available.
Baraliakos, X, Brandt, J, Listing, J, Sieper, J, Braun, J
No abstract available.
Baraliakos, X, Listing, J, Brandt, J, Rudwaleit, M, Sieper, J, Braun, J
No abstract available.
Baraliakos, X, Listing, J, Rudwaleit, M, Brandt, J, Sieper, J, Braun, J
No abstract available.
Efficacy and Safety of Infliximab in Patients With Ankylosing Spondylitis (2005)
Dijkmans, B., Sieper, J., DeWoody, K., Williamson, P., ...
Objective. The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, and diseasemodifying antirheumatic drugs in quite a...
Efficacy and Safety of Infliximab in Patients With Ankylosing Spondylitis (2005)
Dijkmans, B., Sieper, J., DeWoody, K., Williamson, P., ...
Objective. The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, and diseasemodifying antirheumatic drugs in quite a...
Efficacy and Safety of Infliximab in Patients With Ankylosing Spondylitis (2005)
Dijkmans, B., GEUSENS, Piet, Sieper, J., DeWoody, K., Williamson, P., ...
Objective. The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, and diseasemodifying antirheumatic drugs in quite a...
T cell response in Shigella-induced reactive arthritis (2004)
Brandt, H, Stelzl, U, Kuon, W, Adam, T, Nierhaus, KH, Sieper, J
No abstract available.
Dijkmans, B, Sieper, J, DeWoody, K, Williamson, R, Braun, J, VAN DER HEIJDE, Desiree, ...
Univ Hosp Maastricht, Dept Rheumatol, Maastricht, Netherlands. Vrije Univ Amsterdam, Acad Ziekenhuis, Dept Rheumatol, Amsterdam, Netherlands. Limburgs Univ Ctr, Diepenbeek, Belgium. Free Univ Berlin,...
Dijkmans, B, Sieper, J, DeWoody, K, Williamson, R, Braun, J, VAN DER HEIJDE, Desiree, ...
Univ Hosp Maastricht, Dept Rheumatol, Maastricht, Netherlands. Vrije Univ Amsterdam, Acad Ziekenhuis, Dept Rheumatol, Amsterdam, Netherlands. Limburgs Univ Ctr, Diepenbeek, Belgium. Free Univ Berlin,...
Sieper, J, Rudwaleit, M, Braun, J, VAN DER HEIJDE, Desiree
Free Univ Berlin, Klinikum Benjamin Franklin, D-12200 Berlin, Germany. German Rheumatol Res Ctr, Berlin, Germany. Univ Hosp Maastricht, Maastricht, Netherlands. Limburgs Univ Ctr, Diepenbeek,...
Sieper, J, Rudwaleit, M, Braun, J, VAN DER HEIJDE, Desiree
Free Univ Berlin, Klinikum Benjamin Franklin, D-12200 Berlin, Germany. German Rheumatol Res Ctr, Berlin, Germany. Univ Hosp Maastricht, Maastricht, Netherlands. Limburgs Univ Ctr, Diepenbeek,...
Divergent T-cell cytokine patterns in inflammatory arthritis.
Simon, A K, Seipelt, E, Sieper, J
A major immunoregulatory mechanism in inflammatory infections and allergic diseases is the control of the balance of cytokines secreted by Th1/Th2 subsets of T helper (Th) cells. This might also be...
Divergent T-cell cytokine patterns in inflammatory arthritis.
Simon, A K, Seipelt, E, Sieper, J
A major immunoregulatory mechanism in inflammatory infections and allergic diseases is the control of the balance of cytokines secreted by Th1/Th2 subsets of T helper (Th) cells. This might also be...
Jobanputra, P, Choy, E H, Kingsley, G H, Sieper, J, Palacios-Boix, A A, Heinegård, D, ...
Cellular immunity to cartilage proteoglycans may be responsible for sustaining chronic inflammation in ankylosing spondylitis. This hypothesis was examined by measuring peripheral blood and synovial...
Braun, J, Laitko, S, Treharne, J, Eggens, U, Wu, P, Distler, A, ...
OBJECTIVE--To examine whether reactive arthritis (ReA) known to occur after a urogenital infection with Chlamydia trachomatis can also follow an infection with Chlamydia pneumoniae, a recently...
Sieper, J, Braun, J, Döring, E, Wu, P, Heesemann, J, Treharne, J, ...
BACKGROUND: The cause of juvenile chronic arthritis (JCA) is unknown. Pauciarticular JCA is the most common subtype and can be subdivided into early (type I) and late onset (type II) forms, the...
Anatomy and biochemistry of entheses
BENJAMIN, M., BOLLOW, M., BRAUN, J., BRANDT, J., BRAUN, J., BRAUN, J., ...
Bollow, M, Fischer, T, ReiBhauer, H, Backhaus, M, Sieper, J, Hamm, B, ...
OBJECTIVE—Sacroiliitis is a hallmark of the spondyloarthropathies (SpA). The degree of inflammation can be quantified by magnetic resonance imaging (MRI). The aim of this study was to further...
Rudwaleit, M., Yin, Z., Siegert, S., Grolms, M., Radbruch, A., Braun, J., ...
OBJECTIVE—This study was performed to assess whether there is any change in the T cell cytokine pattern in early rheumatoid arthritis (RA) patients treated with methotrexate (MTX) and whether the...
Rudwaleit, M, Siegert, S, Yin, Z, Eick, J, Thiel, A, Radbruch, A, ...
OBJECTIVE—To test the hypothesis that ankylosing spondylitis (AS) is a T helper cell type 2 polarised disease by quantifying the T cell cytokines interferon γ (IFNγ), interleukin 4 (IL4),...
Low incidence of reactive arthritis in children following a salmonella outbreak
Rudwaleit, M, Richter, S, Braun, J, Sieper, J
OBJECTIVES—To assess the incidence of reactive arthritis (ReA) in an outbreak of salmonella infection in a large cohort of children in Germany. METHODS—A few days after the salmonella outbreak...
Fendler, C, Laitko, S, Sorensen, H, Gripenberg-Lerche, C, Groh, A, Uksila, J, ...
OBJECTIVE—Reactive arthritis (ReA) triggered by Chlamydia trachomatis or enteric bacteria such as yersinia, salmonella, Campylobacter jejuni, or shigella is an important differential diagnosis in...
Atopic disorders in ankylosing spondylitis and rheumatoid arthritis
Rudwaleit, M, Andermann, B, Alten, R, Sorensen, H, Listing, J, Zink, A, ...
Background: The prevalence of atopic disorders in ankylosing spondylitis (AS) is unknown. AS and rheumatoid arthritis (RA) exhibit divergent T helper (Th) cell cytokine patterns.
Zou, J, Rudwaleit, M, Brandt, J, Thiel, A, Braun, J, Sieper, J
Objective: To assess the change in the cytokine secreting ability of CD4+ and CD8+ T cells and macrophages during etanercept treatment.
Braun, J, Pham, T, Sieper, J, Davis, J, Dougados, M, ...
Objective: To obtain an international consensus about the use of anti-tumour necrosis factor α (anti-TNFα) for treating patients with ankylosing spondylitis (AS).
Braun, J., Xiang, J., Brandt, J., Maetzel, H., Haibel, H., Wu, P., ...
Background: There is currently no universal consensus on nomenclature for spondyloarthropathy (SpA), or on activity and severity criteria for ankylosing spondylitis (AS).
Ankylosing spondylitis: an overview
Sieper, J, Braun, J, Rudwaleit, M, Boonen, A, Zink, A
Ankylosing spondylitis (AS) is a complex, potentially debilitating disease that is insidious in onset, progressing to radiological sacroiliitis over several years. Patients with symptomatic AS lose...
Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience
Braun, J, Sieper, J, Breban, M, Collantes-Estevez, E, Davis, J, Inman, R, ...
The conventional approach to treatment of patients with spondyloarthritis (SpA), particularly ankylosing spondylitis (AS), has serious limitations, adding a sense of urgency to the evaluation of new...
Staging of patients with ankylosing spondylitis: a preliminary proposal
Braun, J, Dougados, M, Emery, P, Khan, M, Sieper, J, ...
Patients with ankylosing spondylitis (AS) are characterised by a wide range of clinical presentations, radiographic profiles, and outcomes, which are not well differentiated by current diagnostic and...
How to diagnose axial spondyloarthritis early
Rudwaleit, M, Khan, M, Braun, J, Sieper, J
Background: Chronic low back pain (LBP), the leading symptom of ankylosing spondylitis (AS) and undifferentiated axial spondyloarthritis (SpA), precedes the development of radiographic sacroiliitis,...
Rudwaleit, M, Listing, J, Brandt, J, Braun, J, Sieper, J
Background: TNFα blockers have been shown to be highly efficacious in patients with active ankylosing spondylitis (AS).
Simon, A K, Seipelt, E, Wu, P, Wenzel, B, Braun, J, Sieper, J
Subpopulations of human T cells (Th0, Th1 and Th2) can be distinguished by their cytokine-secretion pattern. Evidence is increasing from other studies that the outcome of a human disease may depend...
Sieper, J, Braun, J, Wu, P, Kingsley, G
In reactive arthritis (ReA) there is specific proliferation of synovial fluid (SF) mononuclear cells (MNC) to the triggering bacterial antigen; comparatively little or no response is seen in...
Braun, J, Baraliakos, X, Golder, W, Hermann, K, Listing, J, Brandt, J, ...
Objectives: To compare conventional radiography and magnetic resonance imaging (MRI) for detection of chronic changes in the spine of patients with ankylosing spondylitis (AS).
Brandt, J, Listing, J, Sieper, J, Rudwaleit, M, Braun, J
Objective: To develop and compare candidate improvement criteria for anti-TNFα treatment in ankylosing spondylitis with optimal discriminating capacity between treatment and placebo.
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis
Calin, A, Dijkmans, B, Emery, P, Hakala, M, Kalden, J, Leirisalo-Repo, M, ...
Objective: A double blind, randomised, placebo controlled study to evaluate the safety and efficacy of etanercept to treat adult patients with ankylosing spondylitis (AS).
Listing, J, Brandt, J, Rudwaleit, M, Zink, A, Sieper, J, Braun, J
Methods: The data of a 2 year open extension study of a 12 week, double blind, randomised, placebo controlled trial, in which all patients with AS were treated with 5 mg/kg infliximab, were used to...
Six months open label trial of leflunomide in active ankylosing spondylitis
Haibel, H, Rudwaleit, M, Braun, J, Sieper, J
Patients and methods: Twenty patients with AS fulfilling the 1984 modified New York criteria with a Bath AS Disease Activity Index (BASDAI) >3 were given leflunomide for 6 months. Clinical outcome...
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks
Haibel, H, Rudwaleit, M, Listing, J, Sieper, J
Methods: Anakinra (100 mg) was given subcutaneously daily over 24 weeks to 20 NSAID refractory patients with ankylosing spondylitis. Thirteen completed the study. Clinical outcome assessments...
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis
Braun, J, Brandt, J, Listing, J, Zink, A, Alten, R, Burmester, G, ...
Objective: To obtain results of the second year extension of an original 3 month randomised, placebo controlled trial (and the 1 year extension study) assessing the use of infliximab, a monoclonal...
Mertz, A. K., Daser, A., Skurnik, M., Wiesmüller, K. H., Braun, J., Appel, H., ...
BACKGROUND: Reactive arthritis (ReA) is a T cell mediated inflammatory process. The immune response is primarily directed against a triggering organism, although autoimmunity has been invoked in...
Schröder, A. E., Sieper, J., Berek, C.
BACKGROUND: Reactive arthritis (ReA) can develop as a consequence of a bacterial infection with organisms such as Chlamydia trachomata, Shigella flexneri, or Yersinia enterocolitica. Although the...
Braun, J, Landewe, R, Davis, J, Sieper, J, ...
Baraliakos, X, Landewe, R, Hermann, K, Listing, J, Golder, W, Brandt, J, ...
Background: Magnetic resonance imaging (MRI) is increasingly used to detect inflammation in the spine of patients with ankylosing spondylitis (AS).
Analysis of the CD8+ T cell response to the G1 domain of aggrecan in ankylosing spondylitis
Zou, J, Appel, H, Rudwaleit, M, Thiel, A, Sieper, J
Background: CD4+ T cell responses to the G1 domain of aggrecan in patients with ankylosing spondylitis (AS) were recently reported. Whether such an immune response can be seen in the CD8+...
Baraliakos, X, Hermann, K, Landewe, R, Listing, J, Golder, W, Brandt, J, ...
Objectives: To compare the performance of two different MRI sequences—T1 weighted, fat saturated, spin echo after application of contrast medium, and short τ inversion recovery (STIR)...
Rudwaleit, M, Baraliakos, X, Listing, J, Brandt, J, Sieper, J, Braun, J
Objective: To assess the changes in inflammatory lesions of the spine and the sacroiliac (SI) joints as detected by magnetic resonance imaging (MRI) in patients with ankylosing spondylitis (AS) and...
Baraliakos, X, Listing, J, Rudwaleit, M, Brandt, J, Sieper, J, Braun, J
Background: Anti-tumour necrosis factor (TNF) treatment is clinically efficacious in patients with active ankylosing spondylitis (AS) and leads to improvement of spinal inflammation, as assessed by...
Very early spondyloarthritis: where the inflammation in the sacroiliac joints starts
Bollow, M, Hermann, K, Biedermann, T, Sieper, J, Schontube, M, Braun, J
How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?
Recognition and treatment of ankylosing spondylitis (AS) in the early stages of the disease has yet to be established. This paper considers the evidence available and the questions that need to be...